Cargando…
The Impact of p53 Dysfunction in ATR Inhibitor Cytotoxicity and Chemo- and Radiosensitisation
Ataxia telangiectasia mutated and Rad3 related kinase (ATR) signals replication stress and DNA damage to S and G2 arrest and promotes DNA repair. Mutations in p53, critical for G1 checkpoint control, are common in cancer and predicted to confer vulnerability to ATR inhibitors. Reported data on the i...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6116113/ https://www.ncbi.nlm.nih.gov/pubmed/30127241 http://dx.doi.org/10.3390/cancers10080275 |
_version_ | 1783351535523069952 |
---|---|
author | Middleton, Fiona K. Pollard, John R. Curtin, Nicola J. |
author_facet | Middleton, Fiona K. Pollard, John R. Curtin, Nicola J. |
author_sort | Middleton, Fiona K. |
collection | PubMed |
description | Ataxia telangiectasia mutated and Rad3 related kinase (ATR) signals replication stress and DNA damage to S and G2 arrest and promotes DNA repair. Mutations in p53, critical for G1 checkpoint control, are common in cancer and predicted to confer vulnerability to ATR inhibitors. Reported data on the impact of p53 status are variable possibly because of the use of unmatched cells and surrogate endpoints of survival. The cytotoxicity of VE-821 alone and its ability to potentiate radiation and gemcitabine cytotoxicity was determined in isogenic and unmatched p53 wild-type (wt) and null/mutant cells, as well as immortalised nonmalignant MCF10 (immortalised non-neoplastic) cells, by colony-forming assay. The effect on cell cycle checkpoints was determined by flow cytometry. The isogenic p53 defective cells were not more sensitive to VE-821 alone. Defective p53 consistently conferred greater chemo- and radiosensitisation, particularly at high dose levels in isogenic cells but not unmatched cells. VE-821 did not sensitise MCF10 cells. We conclude that p53 status is just one factor contributing to chemo- and radiosensitisation by ATR inhibition, the lack of chemo- or radiosensitisation in the noncancerous cells suggests an element of tumour-specificity that warrants further investigation. The greater sensitisation at high-dose irradiation suggests that ATR inhibitors may be most effective with hypofractionated radiotherapy. |
format | Online Article Text |
id | pubmed-6116113 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-61161132018-08-31 The Impact of p53 Dysfunction in ATR Inhibitor Cytotoxicity and Chemo- and Radiosensitisation Middleton, Fiona K. Pollard, John R. Curtin, Nicola J. Cancers (Basel) Article Ataxia telangiectasia mutated and Rad3 related kinase (ATR) signals replication stress and DNA damage to S and G2 arrest and promotes DNA repair. Mutations in p53, critical for G1 checkpoint control, are common in cancer and predicted to confer vulnerability to ATR inhibitors. Reported data on the impact of p53 status are variable possibly because of the use of unmatched cells and surrogate endpoints of survival. The cytotoxicity of VE-821 alone and its ability to potentiate radiation and gemcitabine cytotoxicity was determined in isogenic and unmatched p53 wild-type (wt) and null/mutant cells, as well as immortalised nonmalignant MCF10 (immortalised non-neoplastic) cells, by colony-forming assay. The effect on cell cycle checkpoints was determined by flow cytometry. The isogenic p53 defective cells were not more sensitive to VE-821 alone. Defective p53 consistently conferred greater chemo- and radiosensitisation, particularly at high dose levels in isogenic cells but not unmatched cells. VE-821 did not sensitise MCF10 cells. We conclude that p53 status is just one factor contributing to chemo- and radiosensitisation by ATR inhibition, the lack of chemo- or radiosensitisation in the noncancerous cells suggests an element of tumour-specificity that warrants further investigation. The greater sensitisation at high-dose irradiation suggests that ATR inhibitors may be most effective with hypofractionated radiotherapy. MDPI 2018-08-20 /pmc/articles/PMC6116113/ /pubmed/30127241 http://dx.doi.org/10.3390/cancers10080275 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Middleton, Fiona K. Pollard, John R. Curtin, Nicola J. The Impact of p53 Dysfunction in ATR Inhibitor Cytotoxicity and Chemo- and Radiosensitisation |
title | The Impact of p53 Dysfunction in ATR Inhibitor Cytotoxicity and Chemo- and Radiosensitisation |
title_full | The Impact of p53 Dysfunction in ATR Inhibitor Cytotoxicity and Chemo- and Radiosensitisation |
title_fullStr | The Impact of p53 Dysfunction in ATR Inhibitor Cytotoxicity and Chemo- and Radiosensitisation |
title_full_unstemmed | The Impact of p53 Dysfunction in ATR Inhibitor Cytotoxicity and Chemo- and Radiosensitisation |
title_short | The Impact of p53 Dysfunction in ATR Inhibitor Cytotoxicity and Chemo- and Radiosensitisation |
title_sort | impact of p53 dysfunction in atr inhibitor cytotoxicity and chemo- and radiosensitisation |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6116113/ https://www.ncbi.nlm.nih.gov/pubmed/30127241 http://dx.doi.org/10.3390/cancers10080275 |
work_keys_str_mv | AT middletonfionak theimpactofp53dysfunctioninatrinhibitorcytotoxicityandchemoandradiosensitisation AT pollardjohnr theimpactofp53dysfunctioninatrinhibitorcytotoxicityandchemoandradiosensitisation AT curtinnicolaj theimpactofp53dysfunctioninatrinhibitorcytotoxicityandchemoandradiosensitisation AT middletonfionak impactofp53dysfunctioninatrinhibitorcytotoxicityandchemoandradiosensitisation AT pollardjohnr impactofp53dysfunctioninatrinhibitorcytotoxicityandchemoandradiosensitisation AT curtinnicolaj impactofp53dysfunctioninatrinhibitorcytotoxicityandchemoandradiosensitisation |